May 14, 2009

VSRI and CCMR Advisory Board organized a unique mind exchange forum, where Chinese top tier medical thought leaders and R & D leaders of major multi-national pharmaceutical companies came together to explore a new paradigm of collaboration - evidence based medicine, aiming for a professional, productive, and prevailing joint force.

Prof Da Yi Hu , Prof Li Nong Ji, Prof Yi Ming Mu, Prof Guang Ning, Prof Hui Tian, Dr. Junping Kang attended the meeting and shared their and determination on leading the medical practice in China with evidence and not with influence.

Prof Da Yi Hu commented, "Today we in China are participating in more than half of the major multi-national investigational clinical trials conducted around world. However, we know little about how Chinese population in large may respond to those new medical interventions". 

Prof Li Nong Ji and Yi Ming Mu both said, "We are the leader of Chinese Endocrinologists Association. However we have no ideas whether our physicians are following the medical guidelines, and if not, why not"...."We need to conduct more, a lot more, real world outcomes research to better understand the gaps between what should be done and what are being done".

Prof Li Nong Ji introduced a diabetes registry that CCMR is planning to conduct, called "A Comprehensive Cohort Study in Type 2 Diabetes in China", or CCDC. He encouraged industry to be the share holders of this largest and most thorough cross sectional and longitudinal registry ever being planned in China.

Madam Ling Zhi Kong, deputy director of Chronic Disease Control, Ministry of Health, came to deliver a speech on what does the recently announced health reform in China mean and how will it impact on medical communities and medical industries.

R & D leaders from Johnson & Johnson, Roche, Sanofi-Aventis, and Novo Nordisk attended the MindXchange forum. They were very impressed by the level of determination among national top tier opinion leaders on better generating and better understanding real world clinical outcomes data in China.

"Data from RCT (Randomized and Controlled Trials) get your products approved in the world, but the real world clinical evidence would help us use your products in China" 

This is the strongest message that the industry representatives learned.

Click here for FINAL PROGRAM of this event.

Click here for PHOTO ALBUM of this event.